InnoMicro is an innovative biological drug developer for immunotherapy. It is committed to the research, development, production and sales of oncolytic immune dual therapy drugs for tumors. It uses herpes virus to transform therapeutic tumor vaccines and provides users with a new generation of oncolytic viruses. product. Recently, Einuo Micropharmaceutical received a new round of financing of 8 million US dollars. The investor is China Merchants China Fund. The post-investment valuation is US$500 million, accounting for 1.6%.
This article is reproduced from: https://www.itjuzi.com/investevent/13583429
This site is for inclusion only, and the copyright belongs to the original author.